1. Generics Bulletin
  2. >>Business
  3. >>Deals

Stada Settlements Secure Squeeze-Out

Nidda Agrees To Payout For Remaining Shareholders To Take 100% Ownership

 
• By Dave Wallace

Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of €0.10 per outstanding share for the remaining shareholders.

Euro coins
Nidda will pay out an additional €0.10 per outstanding Stada share • Source: Shutterstock

Stada owner Nidda Healthcare, the investment vehicle controlled by Bain Capital Private Equity and Cinven Partners, says it has secured a “timely” squeeze-out of remaining Stada shareholders through settlement deals that will allow it to take 100% ownership of the German generics, biosimilars and consumer healthcare giant.

As of 5 June 2020, Nidda held 60,886,128 shares in Stada, representing around 97.7% of the company’s total. This was built up from the 93.7% that was held by Nidda at the end of 2018 after completing a public delisting tender offer. (Also see "Bain and Cinven cement Stada" - Generics Bulletin, 23 November, 2018.) In August, Nidda announced that the cash compensation for remaining minority shareholders would be set at €98.51 ($115

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Adalvo And Gedeon Richter Join Forces On Semaglutide

 
• By Dave Wallace

Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

More from Business

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.